RHOA and inflammatory bowel disease: By interrupting the RhoA/ROCK pathway, Y-27632 has been shown to improve TNBS-induced colitis in rat by inhibiting NF-κB activation [116], alleviating DSS-induced intestinal inflammation by regulating cell function and cytokine secretion [180], and repress fibrogenesis by blocking RhoA/ROCK/MYLK/SRF signaling in colonic myofibroblasts, representing a new therapy for intestinal fibrosis in IBD patients [117].